TRI-TEST 200 Injectable Recalled for Lack of Sterility Assurance
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling TRI-TEST 200 injectable medication due to lack of assurance of sterility. Affected lots include T1007302021:37 and T1008242021:04.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a sterility assurance failure in an injectable drug. Loss of sterility assurance in injectable medications poses a direct risk of serious infection and is classified as a severe safety hazard under the rubric criteria for Class II recalls with risk of serious adverse outcomes.
Plain-English summary
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling TRI-TEST 200 (CY50%-EN37.5%-PR12.5%) injectable medication distributed in the United States, including Washington, D.C. and Puerto Rico. The recall affects 4 vials with lot numbers T1007302021:37 (BUD 01/26/2022) and T1008242021:04 (BUD 02/20/2022).
The reason for the recall is lack of assurance of sterility. Sterility is a critical requirement for injectable medications to prevent serious infections.
Patients who have received doses from these lots should contact their healthcare provider immediately. Healthcare providers should review patient records to identify those who may have received the affected product and take appropriate action.
The recalled product
- Product
- TRI-TEST 200 (CY50%-EN37.5%-PR12.5%) INJ #1 200MG/ML INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
- Manufacturer
- Vita Pharmacy, LLC dba Talon Compounding Pharmacy
- Category
- Drug — Injectable / Compounded
- Hazard
- sterility-assurance-failure
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: T1007302021:37 BUD: 01/26/2022
- T1008242021:04 BUD: 02/20/2022
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27